Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer

Published:2021-04-13 Issue:3 Volume:6 Page:161-171
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

Reungwetwattana Thanyanan¹,Rohatgi Nitesh²,Mok Tony S.³,Prabhash Kumar⁴

Affiliation:

1. Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

2. Department of Medical Oncology, Max Super Speciality Hospital, New Delhi, India

3. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China

4. Medical Oncology, Tata Memorial Hospital, Mumbai, India

Funder

Pfizer Inc

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2021.1909420

Reference71 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Non-small cell lung cancer: current treatment and future advances

3. Overview of current systemic management of EGFR-mutant NSCLC

4. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

5. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

2. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer;Beilstein Journal of Nanotechnology;2023-02-22

3. Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer;Handbook of Oncobiology: From Basic to Clinical Sciences;2023

4. Targeting phospholipase C using synthetic inhibitors of EGFR signaling for cancer treatment;Phospholipases in Physiology and Pathology;2023

5. Molecular targeted therapy for anticancer treatment;Experimental & Molecular Medicine;2022-10-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3